Heart failure with preserved ejection fractionĬondition being studied is a rare disease Esto aumenta carga de trabajo del corazón derecho y puede conducir a insuficiencia cardíaca derecha.ĭiseases - Cardiovascular Diseases Į.1.2 Medical condition or disease under investigation Insuficiencia cardíaca izquierda puede conducir a mayor presión en los vasos sanguíneos del pulmón. ![]() This increases the right heart workload and may lead to right heart failure. Left heart failure (inability of the heart to pump enough blood) may lead to increased pressure in the lung blood vessels. Medical condition in easily understood language Insuficiencia cardíaca con fracción de eyección preservada y vasculopatía pulmonar Heart failure with preserved ejection fraction and pulmonary vascular disease Medicinal product containing genetically modified organismsĮ.1 Medical condition or disease under investigation Immunological medicinal product (such as vaccine, allergen, immune serum) one involving a medical device)Ĭommittee on Advanced therapies (CAT) has issued a classification for this productĬombination product that includes a device, but does not involve an Advanced Therapy The IMP has been designated in this indication as an orphan drug in the Communityĭ.3.8 to D.3.10 IMP Identification Details (Active Substances)Īctive substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)Ĭombination ATIMP (i.e. Name of the Marketing Authorisation holderĬountry which granted the Marketing Authorisation IMP to be used in the trial has a marketing authorisation Status of the IMP to be used in the clinical trial Trial is part of a Paediatric Investigation PlanĮMA Decision number of Paediatric Investigation Plan Name or abbreviated title of the trial where available Un estudio para evaluar si macitantan es un tratamiento eficaz y seguro para pacientes con insuficiencia cardíaca con fracción de eyección preservada y enfermedad vascular pulmonar non-technical, languageĪ study to evaluate whether macitentan is an effective and safe treatment for patients with heart failure with preserved ejection fraction and pulmonary vascular disease Title of the trial for lay people, in easily understood, i.e. Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (seeĪ multi-center, double-blind, placebo-controlled Phase 2b study to evaluate the efficacy and safety of macitentan in subjects with heart failure with preserved ejection fraction and pulmonary vascular diseaseĮstudio de fase IIb, multicéntrico, con doble enmascaramiento y controlado con placebo para evaluar la eficacia y la seguridad de macitentan en pacientes con insuficiencia cardíaca con fracción de eyección preservada y vasculopatía pulmonar. Older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006). The register also displays information on The EU Clinical Trials Register currently displaysĬlinical trials with a EudraCT protocol, of whichĪre clinical trials conducted with subjects less than 18 years old. Interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/ECĬlinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine developmentĮU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through theĬlinical Trials Information System (CTIS). * If the individual continues to be at risk of exposure to the disease, revaccination should be considered.Allows you to search for protocol and results information on: Fifth dose 28 days after the first dose. ![]() ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |